Fujirebio

• MRI-derived brain aging trajectories across the Alzheimer's continuum: links to cognition, pathology and lifestyle risk factors

  22 Aug 2026

• Evaluating the association of apolipoprotein E genotype and cognitive resilience in SuperAgers

  1 Jan 2026

• Lifespan Trajectories of Asymmetry in White Matter Tracts

  29 Sept 2025

Sources: api.crossref.org, pubmed.ncbi.nlm.nih.gov

• Air pollution is associated with sex-specific longitudinal changes in astrocytic and neuroinflammatory processes linked to cognitive decline in Alzheimer's disease at-risk individuals

  Fees or honoraria, Grants or research support, 1 Oct 2026

• Different functional connectivity gradients reflect aging and Alzheimer's disease

  Grants or research support, 1 Oct 2026

• Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs

  Fees or honoraria, Grants or research support, 22 Sept 2026

• A scalable workflow using digital cognitive assessment and pTau217 for MCI detection

  Consulting or advice, Board or leadership role, 17 Sept 2026

• Circulating Metabolite Signatures Associated With Amyloid Positivity, Cognitive Performance and Plasma P-tau181 Levels in Cognitively Unimpaired Older Adults

  Fees or honoraria, Grants or research support, 14 Sept 2026

• Matrix metalloproteinase-9 is associated with CX3CL1 on tau and amyloid biomarker pathways in APOE4 carriers

  Fees or honoraria, Grants or research support, 13 Sept 2026

• Parental longevity and polygenic longevity scores in relation to ageing-related factors in a population of 70-year-olds followed over six years: The Gothenburg H70 Birth Cohort Study

  Fees or honoraria, Grants or research support, 11 Sept 2026

• Developmental brain programmes and biomarker activation in Alzheimer's disease

  Fees or honoraria, 3 Sept 2026

• Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study

  Consulting or advice, Fees or honoraria, Board or leadership role, 3 Sept 2026

• Blood-based biomarkers of Alzheimer's disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

  Fees or honoraria, Grants or research support, 2 Sept 2026

• Technology-natives and technology-adopters: Age differences in remote cognitive assessment in Alzheimer disease

  Consulting or advice, Fees or honoraria, 1 Sept 2026

• Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome

  Consulting or advice, Fees or honoraria, Board or leadership role, 1 Sept 2026

• Incidence of dementia and mild cognitive impairment in two Indigenous Bolivian cohorts

  Fees or honoraria, Grants or research support, 1 Sept 2026

• Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing

  Fees or honoraria, Grants or research support, 24 Aug 2026

• Regional amyloid accumulation, post-traumatic distress, and intrusive symptoms in cognitively unimpaired older adults at risk for Alzheimer's

  Grants or research support, 18 Aug 2026

• Cognitive components derived from traditional neuropsychological tests and their associations with plasma p-tau217 and p-tau181 in mild cognitive impairment: a multisite analysis

  Fees or honoraria, Grants or research support, 12 Aug 2026

• Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers

  Fees or honoraria, Grants or research support, 12 Aug 2026

• Plasma Biomarkers for Neocortical Tau Burden

  Fees or honoraria, 10 Aug 2026

• Lifestyle and psychosocial protective factors drive healthy aging and modulate inflammatory and metabolic pathways

  Fees or honoraria, Grants or research support, 5 Aug 2026

• Astrocyte reactivity modifies the effects of locus coeruleus norepinephrine-related dysfunction on tau and its impact on cognition

  Fees or honoraria, Grants or research support, 1 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Glycovariants of CA-125 in the early detection of ovarian cancer

  medRxiv : the preprint server for health sciences, 24 Sept 2026

• Establishing age-stratified reference values for blood Neurofilament Light chain (NfL) using the Lumipulse® platform

  Revue neurologique, 22 May 2026

• Accuracy of an Automated Plasma Apolipoprotein E4 Proteotyping Immunoassay for Determination of APOE Genotype

  AAIC 2025 abstract, 9 Jan 2026

• Acute effects of lactate infusion on metabolism, AD biomarkers, and cognition; the LEAN study

  AAIC 2025 abstract, 8 Jan 2026

• Classification performance of the Lumipulse ® G pTau 217 Plasma assay and Lumipulse ® G pTau 217/β‐Amyloid 1‐42 Plasma Ratio in a preclinical cohort

  AAIC 2025 abstract, 8 Jan 2026

• Long‐term cognitive and biomarker trajectories of cognitively unimpaired individuals with different levels of plasma ptau‐217

  AAIC 2025 abstract, 8 Jan 2026

• VeraBIND Tau test, a novel plasma assay for active tau pathology, identifies individuals with positive tau‐PET signal, regardless of amyloid status

  AAIC 2025 abstract, 7 Jan 2026

• Combining Lumipulse pTau217 and Aβ42 as confirmatory tests for Aβ pathology prior to DMT

  AAIC 2025 abstract, 7 Jan 2026

• Comparison of plasma pTau217 assays on different platforms

  AAIC 2025 abstract, 25 Dec 2025

• Real‐World Experience With Plasma PTAU217 as a Screening Tool of Patients at Risk of Alzheimer's Disease in a Memory Clinic

  AAIC 2025 abstract, 25 Dec 2025

• Alzheimer disease blood biomarkers and cognition in midlife

  AAIC 2025 abstract, 25 Dec 2025

• Comparison of two automated ApoE4 proteotype immunoassays

  AAIC 2025 abstract, 25 Dec 2025

• Performance of the Lumipulse plasma p ‐tau217 assay to assess eligibility for amyloid‐lowering therapies

  AAIC 2025 abstract, 24 Dec 2025

• Plasma p ‐tau217 Predicting Concurrent Aβ and Longitudinal Tau Across the Brain

  AAIC 2025 abstract, 23 Dec 2025

• Clinical use of blood ptau217: plasma or serum? The matrix matters

  AAIC 2025 abstract, 23 Dec 2025